Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Notice of Shareholder Update Webinar 20 August 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that it will host a shareholder webinar at 1:00pm AEST (11:00am AWST) on Tuesday, 26 August 2025. During the webinar, CEO and Managing Director, Dr. Michael Thurn and other members of the executive team will provide an update on the following:  Topline results from the 12-month Open Label Extension (OLE) Study using NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS)  Ongoing efforts to expedite the FDA’s review of the Clinical Hold Complete Response for NUZ-001’s Investigational New Drug (IND) application  Continued preclinical initiatives  Outlook on the Company’s near-term objectives The briefing will be followed by a Q&A session. Questions can be submitted now to enquiries@neurizon.com, during online registration, or in written form during the webinar. Anyone wishing to attend the webinar must register via the following:   Registration: https://bit.ly/26082025 Date and time: 1:00pm AEST (11:00am AWST) on Tuesday, 26 August 2025 For those who cannot attend the webinar, a recording will be made available via the Company’s website. -ENDSThis announcement has been authorized for release on behalf of the Neurizon Board by Dr. Michael Thurn, Managing Director and Chief Executive Officer. For further information, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Lidija Damjanovic Head of Markefing and Corporate Affairs Neurizon Therapeufics Limited lidija@neurizon.com +61 (0) 425 700 504 Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222